is tirzepatide coming off the shortage list FDA says weight-loss drug over The recent announcement that Tirzepatide

Peminda Cabandugama, MD, an endocrinologist and obesity medicine specialist at Cleveland Clinic in Ohio, found the results to be slightly surprising. The pharmacokinetics [how drugs move through the body] of GLP-1 medications show a half-life of 5 days, which means the current standard of using these medications every 7 days is also stretching this out, says Dr

Thus, GLP-1 receptor agonists can stabilize the atherosclerotic plaques, provide protection against MACEs, and lower blood pressure, which all produce beneficial cardiovascular effects for the patient.7 As the benefits of the GLP-1 receptor agonists with T2D, obesity, and cardiovascular health are becoming widely known, research into using these agents to treat other conditions has accelerated

While take-up is uncertain, interest in the program among potentially eligible Medicare beneficiaries is likely to be strong

Food Additives & Ingredients - Omega-3 Fatty Acids Market (2022)